Perspectives on Adherence from the ACTG 5360 MINMON Trial: A Minimum Monitoring Approach with 12 Weeks of Sofosbuvir/Velpatasvir in Chronic Hepatitis C Treatment.

Leonard A SowahLaura SmeatonIrena BratesDebika BhattacharyaBenjamin LinasBruce KreterSandra Wagner-CardosoSunil SolomonMark SulkowskiGregory K Robbins

Published in: Clinical infectious diseases : an official publication of the Infectious Diseases Society of America (2023)

Self-reported optimal adherence at week 4 was associated with SVR. Early self-reported adherence could be used to identify those at higher risk of treatment failure and may benefit from additional support. Younger individuals < 30 years may also be prioritized for additional adherence support.

Keyphrases

hepatitis c virus
clinical trial
glycemic control
type diabetes
metabolic syndrome
adipose tissue
skeletal muscle
insulin resistance
phase ii
gestational age